The search for signs in the human body that can be effective in screening and preventing Alzheimer’s disease (AD) is never ending. In a recently published on the online issue of Neurology, the medical journal of the American Academy of Neurology, on July 18th, researchers from Mayo Clinic, John Hopkins University School of Medicine, and Columbia University share their findings of about the series of serum ceramides that are possibility linked with the development of AD. Previous studies have associated serum ceramides with memory impairment and volume loss in the hippocampus. This cohort study involved two types of fatty molecules, sphingomyelins and ceramides. Ceramides are involved in the production of the precursors of amyloid, which can form into insoluble plaques in the brain and lead to AD. The participants were 99 women in the Women’s Health and Aging Study II, and all were without dementia and within the age range of 70 to 79. Their blood was tested, and levels of sphingomyelins and ceramides were measured. They were split into three groups, high, middle, and low, based on the levels of ceramides in their blood. All 99 were registered to be in a prospective study and checked on for up to six visits over nine years. The results showed that 27 of the 99 participants had developed incident dementia, and of the 27, two-thirds received a diagnosis of probable AD. In relation to the level of ceramides found in their blood, those in the high group were ten times at risk for AD than those in the low group, while those in the middle group were eight times more at risk.

These results are significant, as they are consistent with previous research and could possibly provide an economical, convenient, and accurate biomarker for AD. Further studies will need to be conducted with a larger and more diverse study group to confirm these findings.

Keywords: Alzheimer’s disease; serum ceramides; biomarker



Wendy Liu

July 25, 2012

Recent studies in at this month’s Alzheimer’s Association International Conference in Vancouver, Canada has shown that the way a person walks is linked to cognitive function. That is, the speed and style by which a person walks correlates with cognitive changes that may eventually lead to the development of Alzheimer’s disease (AD). Signs of cognitive failure include walking at a slower pace, and fluctuated or uncontrolled walking. Usual studies of AD involve patients who do not move, but the thinking capabilities of the human brain have a strong relationship with its movement skills. While research for the link between walking and mental function has been going on for the past decade, it has been recently taken into new heights because these studies have revealed more specifics about the relationship. For example, the variation and pace in walking is linked with a person’s ability to plan and organize, while rhythm is associated with the speed by which information is processed. The decline in cognitive functions has a parallel relationship with a decrease in walking speed. Newer studies have been incorporated more detailed and advanced approaches than previous research in terms of measuring changes in gait, such as making the participants multitask or having them use electronic walkways.  These studies may lead to a new method in which symptoms of AD can be detected earlier on, as to prevent the development of the disease. It also reinforces the idea that dementia can be delayed with an activity that should be common to humankind, exercise.

For further details on these studies and on Alzheimer’s disease, please visit:

Keywords: Alzheimer’s disease; walking; exercise; cognitive functions

Wendy Liu

July 24, 2012